Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis

Overview

Journal Front Pharmacol

Date 2021 Jun 28

PMID 34177562

Citations 1

Authors

Rui Hu

Ya-Feng Song

Zhi-Yan Yang

Chao Zhang

Bo Tan

Affiliations

Soon will be listed here.

Abstract

Osteoarthritis (OA) high disability rate will increase as people getting older, and is the most prevalent form of arthritis in the future. This study identified the clinical effects of optimum doses of tanezumab for patients with OA. Three electronic databases were searched up until January 15, 2021. The mean difference (MD) or odds ratio (OR) was considered an effect measure. The design-by-treatment interaction model was adopted for network meta-analyses. Analyses were conducted using WinBUGS 1.4.3 and R 4.0.5 software. nine publications with 10 studies were included. Compared with placebo in network meta-analysis, except the outcomes of Western Ontario and McMaster Universities Osteoarthritis (WOMAC) stiffness subscale and joints replaced, all dosages of tanezumab in the other effectiveness outcome were superior to placebo, and the difference was statistically significant. However, there was no statistical difference among all different doses of tanezumab. Compared with placebo, except the outcomes of adverse events (AEs) and AEs of abnormal peripheral sensation, all different dosages of tanezumab weren't superior to placebo in the other effectiveness outcome, and the difference was statistically significant. The 10 mg of tanezumab with highest SUCRA had the best effect, but it was associated with a higher safety event. Compared with placebo, except the outcomes of WOMAC stiffness subscale and joints replaced, all dosages of tanezumab in the other effectiveness outcome were superior to placebo, and the difference was statistically significant. Compared with placebo, except for the outcomes of AEs and AEs of abnormal peripheral sensation, all dosages of tanezumab in the other effectiveness outcome were superior to placebo, and the difference was statistically significant. Other direct comparisons showed no statistical difference. This study recommended that clinicians should give priority to the treatment of OA patients with a low dose of 2.5 mg according to the patient's condition and actual situation. If the effect using tanezumab with 2.5 mg is not satisfactory, the increase up to 10 mg should be carefully pondered, because of a more unbalanced risk/benefit ratio.

Citing Articles

Monoclonal Antibodies for Chronic Pain Treatment: Present and Future.

Sanchez-Robles E, Giron R, Paniagua N, Rodriguez-Rivera C, Pascual D, Goicoechea C Int J Mol Sci. 2021; 22(19).

PMID: 34638667 PMC: 8508878. DOI: 10.3390/ijms221910325.

References

Zhu W, Oxford G . Phosphoinositide-3-kinase and mitogen activated protein kinase signaling pathways mediate acute NGF sensitization of TRPV1. Mol Cell Neurosci. 2007; 34(4):689-700. PMC: 2699283. DOI: 10.1016/j.mcn.2007.01.005. View

Fan Z, Ma J, Wang Y, Chen H, Lang S, Ma X . Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials. Clin Rheumatol. 2020; 40(6):2155-2165. DOI: 10.1007/s10067-020-05488-4. View

Brown M, Herrmann D, Goldstein M, Burr A, Smith M, West C . Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci. 2014; 345(1-2):139-47. DOI: 10.1016/j.jns.2014.07.028. View

Tive L, Bello A, Radin D, Schnitzer T, Nguyen H, Brown M . Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019; 12:975-995. PMC: 6430070. DOI: 10.2147/JPR.S191297. View

Salanti G, Ades A, Ioannidis J . Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2010; 64(2):163-71. DOI: 10.1016/j.jclinepi.2010.03.016. View

Balanescu A, Feist E, Wolfram G, Davignon I, Smith M, Brown M . Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis. 2013; 73(9):1665-72. DOI: 10.1136/annrheumdis-2012-203164. View

Brown M, Murphy F, Radin D, Davignon I, Smith M, West C . Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain. 2012; 13(8):790-8. DOI: 10.1016/j.jpain.2012.05.006. View

Lane N, Schnitzer T, Birbara C, Mokhtarani M, Shelton D, Smith M . Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010; 363(16):1521-31. PMC: 6896791. DOI: 10.1056/NEJMoa0901510. View

Hochberg M, Tive L, Abramson S, Vignon E, Verburg K, West C . When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis Rheumatol. 2015; 68(2):382-91. DOI: 10.1002/art.39492. View

10.

. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. Int Dig Health Legis. 1997; 48(2):231-4. View

11.

Watt F, Gulati M . New Drug Treatments for Osteoarthritis: What is on the Horizon?. Eur Med J Rheumatol. 2018; 2(1):50-58. PMC: 6198938. View

12.

Ghilardi J, Freeman K, Jimenez-Andrade J, Coughlin K, Kaczmarska M, Castaneda-Corral G . Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum. 2012; 64(7):2223-32. PMC: 3386465. DOI: 10.1002/art.34385. View

13.

Chevalier X, Eymard F, Richette P . Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol. 2013; 9(7):400-10. DOI: 10.1038/nrrheum.2013.44. View

14.

Spierings E, Fidelholtz J, Wolfram G, Smith M, Brown M, West C . A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013; 154(9):1603-1612. DOI: 10.1016/j.pain.2013.04.035. View

15.

Karsdal M, Verburg K, West C, Bay-Jensen A, Keller D, Arends R . Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients. Osteoarthritis Cartilage. 2018; 27(3):484-492. DOI: 10.1016/j.joca.2018.12.001. View

16.

Kan S, Li Y, Ning G, Yuan Z, Chen L, Bi M . Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis. PLoS One. 2016; 11(6):e0157105. PMC: 4905652. DOI: 10.1371/journal.pone.0157105. View

17.

Schnitzer T, Ekman E, Spierings E, Greenberg H, Smith M, Brown M . Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2014; 74(6):1202-11. DOI: 10.1136/annrheumdis-2013-204905. View

18.

Yu Y, Lu S, Sun J, Zhou W . Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials. Pain Med. 2020; 22(3):585-595. DOI: 10.1093/pm/pnaa260. View

19.

Berenbaum F, Blanco F, Guermazi A, Miki K, Yamabe T, Viktrup L . Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis. 2020; 79(6):800-810. PMC: 7286052. DOI: 10.1136/annrheumdis-2019-216296. View

20.

Dimitroulas T, Lambe T, Klocke R, Kitas G, Duarte R . Biologic drugs as analgesics for the management of osteoarthritis. Semin Arthritis Rheum. 2017; 46(6):687-691. DOI: 10.1016/j.semarthrit.2016.12.001. View